Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,622 | 135 | 95.5% |
| Education | $124.13 | 4 | 4.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| OPKO Pharmaceuticals, LLC | $307.28 | 18 | $0 (2023) |
| Amgen Inc. | $277.92 | 17 | $0 (2022) |
| Mallinckrodt Enterprises LLC | $240.96 | 7 | $0 (2019) |
| Travere Therapeutics, Inc. | $197.92 | 9 | $0 (2024) |
| Shire North American Group Inc | $196.34 | 9 | $0 (2019) |
| Horizon Therapeutics plc | $193.11 | 5 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $188.88 | 11 | $0 (2023) |
| Mallinckrodt Hospital Products Inc. | $121.05 | 6 | $0 (2023) |
| AKEBIA THERAPEUTICS INC | $105.42 | 5 | $0 (2020) |
| Amarin Pharma Inc. | $97.58 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $68.55 | 3 | Travere Therapeutics, Inc. ($68.55) |
| 2023 | $430.43 | 22 | Mallinckrodt Hospital Products Inc. ($88.38) |
| 2022 | $546.62 | 27 | Horizon Therapeutics plc ($122.82) |
| 2021 | $321.74 | 16 | OPKO Pharmaceuticals, LLC ($135.88) |
| 2020 | $256.32 | 13 | AKEBIA THERAPEUTICS INC ($105.42) |
| 2019 | $499.51 | 19 | Mallinckrodt Enterprises LLC ($180.61) |
| 2018 | $249.53 | 17 | Amgen Inc. ($59.26) |
| 2017 | $373.33 | 22 | Shire North American Group Inc ($154.00) |
All Payment Transactions
139 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/31/2024 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $24.79 | General |
| 05/30/2024 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $25.35 | General |
| 03/19/2024 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $18.41 | General |
| 10/11/2023 | AstraZeneca Pharmaceuticals LP | FLUMIST QUADRIVALENT (Biological) | Food and Beverage | In-kind items and services | $18.34 | General |
| Category: Respiratory | ||||||
| 10/02/2023 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $20.42 | General |
| Category: KRYSTEXXA | ||||||
| 08/16/2023 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $23.35 | General |
| 07/20/2023 | Abbott Laboratories | FREESTYLE LIBRE 2 (Device) | Food and Beverage | In-kind items and services | $16.70 | General |
| Category: Diabetes Care | ||||||
| 07/19/2023 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $22.06 | General |
| Category: IMMUNOLOGY | ||||||
| 07/06/2023 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $27.04 | General |
| 06/22/2023 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $12.81 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 06/21/2023 | Takeda Pharmaceuticals U.S.A., Inc. | GATTEX (Drug) | Food and Beverage | In-kind items and services | $21.48 | General |
| Category: INTERNAL MEDICINE | ||||||
| 06/13/2023 | Kyowa Kirin, Inc. | Crysvita (Drug) | Food and Beverage | In-kind items and services | $21.81 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 06/12/2023 | OPKO Pharmaceuticals, LLC | RAYALDEE (Drug) | Food and Beverage | In-kind items and services | $18.11 | General |
| Category: NEPHROLOGY | ||||||
| 06/07/2023 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $24.40 | General |
| Category: IMMUNOLOGY | ||||||
| 06/01/2023 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $24.69 | General |
| 05/31/2023 | Mallinckrodt Hospital Products Inc. | TERLIVAZ (Drug) | Food and Beverage | In-kind items and services | $16.35 | General |
| Category: CRITICAL CARE | ||||||
| 05/24/2023 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $16.24 | General |
| 05/18/2023 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $25.57 | General |
| Category: IMMUNOLOGY | ||||||
| 04/19/2023 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $13.08 | General |
| Category: IMMUNOLOGY | ||||||
| 03/22/2023 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $14.59 | General |
| Category: Hyperkalemia | ||||||
| 03/02/2023 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $21.05 | General |
| Category: NEPHROLOGY | ||||||
| 02/28/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $19.68 | General |
| 02/23/2023 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $20.74 | General |
| 02/15/2023 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $17.37 | General |
| Category: Hyperkalemia | ||||||
| 02/06/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $14.55 | General |
| Category: Cardiovascular and Metabolism | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 19 | 1,915 | 7,562 | $677,040 | $283,469 |
| 2022 | 38 | 2,472 | 5,623 | $608,345 | $233,448 |
| 2021 | 37 | 2,562 | 5,410 | $603,170 | $247,998 |
| 2020 | 36 | 2,749 | 5,646 | $651,073 | $241,814 |
All Medicare Procedures & Services
130 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99458 | Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | Office | 2023 | 216 | 2,201 | $176,080 | $64,788 | 36.8% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 239 | 1,415 | $134,425 | $49,571 | 36.9% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 238 | 1,385 | $83,100 | $49,125 | 59.1% |
| 90962 | Dialysis services, 1 physician visit per month (20 years or older) | Office | 2023 | 25 | 138 | $60,720 | $20,731 | 34.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 321 | 355 | $35,575 | $15,727 | 44.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 166 | 204 | $33,815 | $14,521 | 42.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 78 | 101 | $21,179 | $10,700 | 50.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 66 | 66 | $18,950 | $10,480 | 55.3% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 13 | 34 | $22,440 | $9,160 | 40.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 82 | 135 | $16,875 | $7,973 | 47.2% |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2023 | 16 | 940 | $15,040 | $5,912 | 39.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 40 | 66 | $10,890 | $5,816 | 53.4% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 81 | 139 | $11,120 | $4,961 | 44.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 31 | 32 | $8,800 | $4,107 | 46.7% |
| 99453 | Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment | Office | 2023 | 205 | 214 | $8,560 | $2,780 | 32.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 25 | 28 | $6,160 | $2,711 | 44.0% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2023 | 33 | 47 | $7,896 | $2,569 | 32.5% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 24 | 25 | $3,750 | $1,444 | 38.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 16 | 37 | $1,665 | $395.16 | 23.7% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2022 | 33 | 194 | $128,040 | $46,480 | 36.3% |
| 90962 | Dialysis services, 1 physician visit per month (20 years or older) | Office | 2022 | 24 | 142 | $62,480 | $21,121 | 33.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 390 | 420 | $42,225 | $20,062 | 47.5% |
| 90966 | Home dialysis services per month (20 years or older) | Office | 2022 | 18 | 92 | $51,060 | $19,235 | 37.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 101 | 166 | $36,938 | $18,218 | 49.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 120 | 275 | $34,375 | $14,429 | 42.0% |
About Dr. Lisa Weber, M.D
Dr. Lisa Weber, M.D is a Specialist healthcare provider based in Wichita, Kansas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/30/2005. The National Provider Identifier (NPI) number assigned to this provider is 1134126436.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lisa Weber, M.D has received a total of $2,746 in payments from pharmaceutical and medical device companies, with $68.55 received in 2024. These payments were reported across 139 transactions from 32 companies. The most common payment nature is "Food and Beverage" ($2,622).
As a Medicare-enrolled provider, Weber has provided services to 9,698 Medicare beneficiaries, totaling 24,241 services with total Medicare billing of $1.0M. Data is available for 4 years (2020–2023), covering 130 distinct procedure/service records.
Practice Information
- Specialty Specialist
- Location Wichita, KS
- Active Since 06/30/2005
- Last Updated 03/16/2011
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1134126436
Products in Payments
- ACTHAR (Biological) $345.66
- RAYALDEE (Drug) $275.93
- GATTEX (Drug) $234.98
- KRYSTEXXA (Biological) $193.11
- Veltassa (Drug) $150.97
- AURYXIA (Drug) $105.42
- Vascepa (Drug) $97.58
- BENLYSTA (Biological) $94.67
- Velphoro (Drug) $80.36
- Prolia (Biological) $67.31
- EVENITY (Biological) $65.59
- LOKELMA (Drug) $65.29
- FARXIGA (Drug) $56.79
- JYNARQUE (Drug) $54.46
- (815) Thiola (Drug) $40.66
- Parsabiv (Biological) $38.21
- KRYSTEXXA (Drug) $36.55
- TARPEYO (Drug) $34.45
- INJECTAFER (Drug) $34.36
- Tavneos (Drug) $32.62
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Wichita
Eva Henry, M.d, M.D
Specialist — Payments: $92,445
Dr. Dennis Ross, M.d, M.D
Specialist — Payments: $28,748
Dr. Matthew Conrad, M.d, M.D
Specialist — Payments: $25,839
Olga Tatpati, M.d, M.D
Specialist — Payments: $5,719
Dr. Lyle Zepick, M.d, M.D
Specialist — Payments: $4,133
Anna Stork-Fury, D.o, D.O
Specialist — Payments: $3,901